Bristol HIV Price Cut Includes Pledge Not To Enforce Patent Rights In Africa
Executive Summary
Bristol-Myers Squibb's HIV drug price cut for sub-Saharan African countries includes a pledge not to enforce patent rights for Videx (didanosine) and Zerit (stavudine).
You may also be interested in...
Abbott Kaletra African AIDS Initiative Could Cost $800 Per Year
Abbott expects the cost of the two HIV drugs it will offer through its distribution initiative in Africa, Kaletra and Norvir, to range between $800 and $1,000 per patient per year.
Abbott Kaletra African AIDS Initiative Could Cost $800 Per Year
Abbott expects the cost of the two HIV drugs it will offer through its distribution initiative in Africa, Kaletra and Norvir, to range between $800 and $1,000 per patient per year.
Mylan Buspirone Launch Awaits Bristol Appeal Of BuSpar Patent Order
Bristol-Myers Squibb appears to have at least two more chances to block a generic version of BuSpar from coming to market following a March 13 preliminary injunction imposed by Judge Ricardo Urbina in Washington, D.C. federal court.